Conversely, the downregulation of ABAT promotes the progression of BLBC (Chen X. et al., 2019) and resistance to endocrine therapy of inflammatory breast cancer (Jansen et al., 2015). The gene discussed is ABAT; the disease is inflammatory breast carcinoma.